Pharmaceutical business integration through the phased acquisition of Daiichi Sankyo Espha

A theme involving the phased acquisition of shares in Daiichi Sankyo Espha to make it a consolidated subsidiary, and the integration and expansion of the pharmaceutical business through product development centered on authorized generics, the sharing of information and expertise, and stable supply.